EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis
Our findings establish EZH2 as a critical regulator of lenvatinib resistance in HCC through ACSL1-mediated ferroptosis suppression. The EZH2-H3K27me3-ACSL1 axis represents a promising therapeutic target for overcoming drug resistance, offering new strategies to improve HCC treatment outcomes.
Authors
- He Cai (ORCID: https://orcid.org/0000-0002-4678-8468)
- Tongchong Zhou (ORCID: https://orcid.org/0000-0002-5179-8038)
- Yibin Zhang (ORCID: https://orcid.org/0009-0008-9862-8803)
- Yucong Lin (ORCID: https://orcid.org/0000-0002-9015-6716)
Institutions
- Third Affiliated Hospital of Guangzhou Medical University (CN)
- Guangzhou Medical University Cancer Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1186/s12885-025-15086-9
- Citations
- 2
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 1.61